Juno Therapeutics Adds To Monday's Gain After Wedbush Upgrade

Juno Therapeutics Inc JUNO shares are trading higher by $7.52, or 20 percent, at $44.00 in Tuesday's session. This comes on top of Monday's gain of $5.75, instigated by Gilead Sciences, Inc. GILD's take over of Kite Pharma Inc KITE at a 30 percent premium to closing price Friday.

The catalyst for Tuesday's rally is an upgrade from Wedbush, who changed their rating from Neutral to Outperform.

After a flat open, it immediately found support just above Monday's closing price ($36.48), only reaching $36.50 before embarking on its major rally. The pace of the rally accelerated once it surpassed Monday's high ($37.50), so far reaching $44.32 as of 11:50 a.m. EST. That marks the highest level since it peaked on June 10, 2016, at $45.00.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechLong IdeasNewsUpgradesTechnicalsM&AIntraday UpdateAnalyst RatingsMoversTrading IdeasGeneralWedbush
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!